Victory Capital Management Inc. grew its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 84.2% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 738,511 shares of the company’s stock after purchasing an additional 337,554 shares during the period. Victory Capital Management Inc. […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) had its target price boosted by stock analysts at Oppenheimer from $75.00 to $79.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s price objective suggests a potential upside of 20.78% from the […]
Teacher Retirement System of Texas grew its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 5.5% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,099 shares of the company’s stock after purchasing an additional 1,203 shares during the quarter. […]
Assenagon Asset Management S.A. lifted its stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 105.2% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,023,507 shares of the company’s stock after acquiring an additional 524,797 shares during the quarter. Assenagon Asset Management S.A. […]
Assenagon Asset Management S.A. raised its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 105.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,023,507 shares of the company’s stock after acquiring an additional 524,797 shares during the quarter. Assenagon Asset Management […]